<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967625</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH-SCLC-01</org_study_id>
    <nct_id>NCT04967625</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC</brief_title>
  <official_title>Anti-PD-1 Antibody Sintilimab Combined With Anti-angeogensis Inhibitor Anlotinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy : a Single-arm Prospective Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a the researchers launched, single-center, prospective, open-label, single arm ,Phase&#xD;
      II clinical study of Sintilimab combined with anlotinib in patients with extensive-stage&#xD;
      disease small-cell lung cancer to evaluate the efficacy and safety.&#xD;
&#xD;
      23 patients are expected to be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive sintilimab 200mg, IV, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W&#xD;
      treatment until disease progression, unacceptable toxicity, or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 26, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Anti-PD-1 antibody sintilimab combined With anti-angeogensis inhibitor anlotinib for extensive stage disease small cell lung cancer after failure of first line standard therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>12 month</time_frame>
    <description>Objective response rate according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>12 months</time_frame>
    <description>Disease control rate according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>12 months</time_frame>
    <description>Duration of response according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
    <description>Progression-free survival according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>on average of 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of adverse event rate according to CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <arm_group>
    <arm_group_label>Sintilimab + Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sintilimab 200mg, IV, d1, Q3W and anlotinib 12mg, PO, QD，d1-14, Q3W; treatment until disease progression, unacceptable toxicity, or death</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>A humanized anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Sintilimab + Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride</intervention_name>
    <description>A tyrosine kinase inhibitor selectively targeting VEGFR-2</description>
    <arm_group_label>Sintilimab + Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18, regardless of gender .&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer .&#xD;
&#xD;
          -  The time after the end of first-line treatment was less than 6 months .&#xD;
&#xD;
          -  Subjects must have measurable diseases as defined in RECIST v1.1 .&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status scores are 0-2 .&#xD;
&#xD;
          -  Adequate hematologic and end organ function .&#xD;
&#xD;
          -  Capable of understanding the trial nature and voluntarily signing the written informed&#xD;
             consent form .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Radiographic findings showed that the tumor involved large blood vessels or was poorly&#xD;
             demarcated from them .&#xD;
&#xD;
          -  Radiographic findings showed significant pulmonary cavitation or necrotizing tumor .&#xD;
&#xD;
          -  Active brain metastasis or meningeal metastasis .&#xD;
&#xD;
          -  With other malignant tumors in the past 5 years, except cancers that have been cured&#xD;
             significantly or can be focally cured, e.g. basosquamous carcinoma of skin, or&#xD;
             carcinoma cervix in situ .&#xD;
&#xD;
          -  With Interstitial lung disease, including drug- induced Interstitial lung disease or&#xD;
             radiation pneumonitis .&#xD;
&#xD;
          -  With clinically significant cardiovascular disorder .&#xD;
&#xD;
          -  Prior exposure to any immune checkpoint inhibitors, including but not limited to other&#xD;
             anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibodies .&#xD;
&#xD;
          -  Prior exposure to anti-VEGFR therapy .&#xD;
&#xD;
          -  Known hypersensitivity to study drug or any of its excipients .&#xD;
&#xD;
          -  Treatment with any other investigational agent or participation in another clinical&#xD;
             trial within 4 weeks prior to first administration .&#xD;
&#xD;
          -  Other conditions that the investigator thinks unsuitable in this study .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guangyuan Lou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lan Shao</last_name>
    <phone>+86 13456964958</phone>
    <email>shaolan28@163.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

